David H. Donabedian, PhD, MBA, is co-founder and CEO of Boston-based Axial Biotherapeutics. Since Axial’s launch in November 2016, David has raised significant capital from top-tier VCs, assembled a renowned advisory and scientific board and established the company as a leader in the gut-brain-axis. David holds a BA in chemistry from St. Anselm College, a Ph.D. in polymer chemistry from the University of Massachusetts Lowell, and an MBA from the University of North Carolina.